Elsevier

Annals of Epidemiology

Volume 21, Issue 11, November 2011, Pages 835-841
Annals of Epidemiology

The Metabolic Syndrome and Risk of Prostate Cancer in Italy

https://doi.org/10.1016/j.annepidem.2011.07.007Get rights and content

Purpose

To provide information on the role of the metabolic syndrome on prostate cancer risk.

Methods

We examined data from a multicentric Italian case-control study. Cases were 1294 patients with incident, histologically confirmed prostate cancer. Controls were 1451 men hospitalized with acute, non-neoplastic conditions. All subjects were younger than 75 years. The metabolic syndrome was defined according to selected indicators of abdominal obesity, hypercholesterolemia, hypertension, and diabetes. We computed multivariate odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression.

Results

Considering separate components of the metabolic syndrome, the ORs were 0.98 (95% CI, 0.72–1.34) for diabetes, 1.14 (95% CI, 0.96–1.36) for hypertension, 1.54 (95% CI, 1.26–1.89) for hypercholesterolemia, and 1.02 (95% CI, 0.86–1.21) for abdominal obesity. The OR of prostate cancer was 1.66 (95% CI, 1.22–2.28) in men with metabolic syndrome compared with those without. We found ORs of 1.02 (95% CI, 0.83–1.26) for men with one component of the metabolic syndrome, 1.12 (95% CI, 0.89–1.42) for two, 1.65 (95% CI, 1.15–2.36) for three, and 3.99 (95% CI, 1.03–15.4) for four compared with no components.

Conclusions

The metabolic syndrome was associated with the risk of prostate cancer in this population.

Introduction

Several definitions of the metabolic syndrome (MetS) have been proposed 1, 2, 3, 4. Efforts have been made to fix a common set of diagnostic criteria, with the aim to allow international comparisons (5). These efforts led to a joint statement of several scientific associations that defined the MetS as the presence of three out of five of the following factors: Elevated waist circumference, elevated triglycerides, reduced high-density lipoprotein (HDL) cholesterol, increased blood pressure, and increased fasting glucose (5).

The prevalence of the MetS is increasing worldwide, together with the interest of the scientific community on its effects on various health outcomes (6), including prostate cancer (7). In fact, although we could not find any epidemiologic investigation published before 2004 (8), at least nine studies on the issue have been made available in the last few years 9, 10, 11, 12, 13, 14, 15, 16, 17. Most investigations were conducted in the United States or in Nordic countries, whereas data from other populations are scanty. Further, findings were largely inconsistent, owing at least in part to different study design, definition of MetS, and outcome (i.e., mortality or incidence) used in different investigations. Two prospective investigations from Northern Europe, one from Finland (8), and one from Norway (13) found an increased risk of prostate cancer. The Finnish study, using the modified World Health Organization definition of the MetS (18), found a relative risk (RR) of 1.94 [95% confidence interval (CI), 1.06–3.53] for men with MetS at baseline, whereas the Norwegian study, based on four MetS components, reported a RR of 1.56 (95% CI, 1.21–2.00). Another analysis from Finland, based on the Helsinki Heart Study which focused on three out of the five components of the MetS, reported an odds ratio (OR) of 3.36 (95% CI, 1.19–9.44) in men with all three components (17). An U.S. case-control study including 637 prostate cancer cases found ORs of 1.71 (95% CI, 0.97–3.01) in African Americans and 1.02 (95% CI, 0.64–1.62) in white men with MetS, defined using a modified version of the Adult Treatment Panel (ATP) III criteria (10). On the other hand, no significant association emerged in cohort studies from Norway (RR, 0.91; 95% CI, 0.77–1.09, MetS defined using ATP III criteria) (14), Japan (RR, 0.76; 95% CI, 0.47–1.22, American Heart Association/National Heart, Lung, and Blood Institute criteria) (11) and the United States (RR, 1.32; 95% CI, 0.63–2.77, ATP III criteria) (12), as well as in an Italian study that linked data from archives of pharmaceutical prescriptions to local Cancer Registries (standardized incidence ratio, 0.93; 95% CI, 0.75–1.14, for subjects prescribed antihypertensive, hypoglycemic, and hypolipemic drugs) (15). Conversely, in the U.S. Atherosclerosis Risk in Communities Study, including 385 cases of prostate cancer, a significant inverse association was found with MetS (defined using ATP III criteria, RR, 0.77; 95% CI, 0.60–0.98) (16).

With the aim to provide further information on the issue from the Mediterranean area, we examined data from an Italian case-control study on risk factors for prostate cancer. Traditional dietary habits of this area, namely, the Mediterranean diet, could reduce the prevalence of the MetS by improving endothelial functions and lowering insulin resistance 19, 20.

Section snippets

Methods

Data were derived from a case-control study of prostate cancer conducted between 1991 and 2002 in the greater Milan area, in the provinces of Pordenone and Gorizia in northern Italy, in the province of Latina in central Italy, and in the urban area of Naples in southern Italy (21). Cases were 1294 men (median age, 66 years; range, 46–74) admitted with incident, histologically confirmed prostate cancer to a network of teaching and general hospitals in the study areas. Controls were 1451 patients

Results

Table 1 gives the distribution of 1294 cases of prostate cancer and 1451 controls, and the corresponding ORs and 95% CI, according to age and selected characteristics. Compared with controls, cases were more educated, reported a lower level of occupational physical activity at age 30, a higher nonalcohol energy intake, and had a family history of prostate cancer more often than controls. Alcohol consumption and smoking habits were similar in cases and controls.

Table 2 shows the distribution of

Discussion

Hypercholesterolemia was the only component of the MetS associated with prostate cancer in this study, confirming previous studies on the issue 26, 27, 28, 29, whereas diabetes, hypertension, and abdominal obesity showed no significant association. Therefore, a major issue was whether the findings observed in this study for the MetS itself, indicating a positive relation with prostate cancer, were meaningful or were merely explained by the association with hypercholesterolemia. When we examined

Conclusions

The MetS was positively associated with the risk of prostate cancer in this population. Men with the MetS had a 66% higher risk compared with those without, and the risk increased with the number of components of the syndrome up to a 4-fold elevated risk for men reporting the presence of all four factors considered in this study in combination.

References (53)

  • A.G. Renehan et al.

    Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

    Lancet

    (2008)
  • A. Tavani et al.

    Diabetes mellitus and the risk of prostate cancer in Italy

    Eur Urol

    (2005)
  • R. Miccoli et al.

    Prevalence of the metabolic syndrome among Italian adults according to ATP III definition

    Nutr Metab Cardiovasc Dis

    (2005)
  • C. Bosetti et al.

    Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls

    J Clin Epidemiol

    (2001)
  • Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

    JAMA

    (2001)
  • S.M. Grundy et al.

    Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary

    Cardiol Rev

    (2005)
  • World Health Organization (WHO)
    (1999)
  • K.G. Alberti et al.

    Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

    Circulation

    (2009)
  • M.A. Cornier et al.

    The metabolic syndrome

    Endocr Rev

    (2008)
  • A.W. Hsing et al.

    Obesity, metabolic syndrome, and prostate cancer

    Am J Clin Nutr

    (2007)
  • J.A. Laukkanen et al.

    Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study

    Cancer Epidemiol Biomarkers Prev

    (2004)
  • J.L. Beebe-Dimmer et al.

    Features of the metabolic syndrome and prostate cancer in African-American men

    Cancer

    (2007)
  • M. Inoue et al.

    Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan

    Eur J Cancer Prev

    (2009)
  • L. Lund Haheim et al.

    Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years

    Am J Epidemiol

    (2006)
  • R.M. Martin et al.

    Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway

    Cancer Causes Control

    (2009)
  • A.J. Tande et al.

    The metabolic syndrome is associated with reduced risk of prostate cancer

    Am J Epidemiol

    (2006)
  • Cited by (40)

    • Diabetes, metabolic syndrome and prostate cancer risk: Results from the EPICAP case-control study

      2022, Cancer Epidemiology
      Citation Excerpt :

      Of the studies that explored the relationship between MetS and PCa risk, most of them did not find any association, either with NCEP-ATP III [19–22, 24], AHA/NHLBI [18] or IDF [20,21] definitions, consistent with our results. Some studies suggested a positive association between NCEP-ATP III [23] and IDF [25] definitions and PCa risk. Other studies found inverse associations between NCEP-ATP III [17,26] and IDF [26] definitions of MetS and PCa.

    • Arterial hypertension in cancer: The elephant in the room

      2019, International Journal of Cardiology
      Citation Excerpt :

      Hypertensive women have been suggested to have higher risk for developing endometrial [8,10] and breast cancer [11]. In men, hypertension is supposed to contribute to the risk of prostate cancer as part of the metabolic syndrome [12]. The metabolic syndrome itself has been advocated as a predisposing factor for cancer development, through diverse pathways [13].

    • Blood lipids profile and lung cancer risk in a meta-analysis of prospective cohort studies

      2017, Journal of Clinical Lipidology
      Citation Excerpt :

      Blood lipids are closely related to systematic lipid metabolism disturbance and cardiovascular disease. Meanwhile, studies have found there is a strong link between serum lipids and cancer morbidity and mortality, such as gastric cancer, gastrointestinal malignancies, and prostate cancer et cetera.3–8 But the association between blood lipids profile and the incidence of lung cancer remains unclear.

    • The metabolic syndrome and cancer: Is the metabolic syndrome useful forpredicting cancer risk above and beyond its individual components?

      2015, Diabetes and Metabolism
      Citation Excerpt :

      A recent meta-analysis reported that the MetS is associated with low to modest increased risks for colorectal, post-menopausal breast, bladder, pancreas, endometrium and liver cancers [5], but for prostate cancer, evidence is conflicting. Some studies report an increased risk [6], others report a decreased risk [7], and others report no association with the MetS [5]. Mechanisms linking the MetS and cancer are not well understood.

    View all citing articles on Scopus

    This work was supported by the Italian Association for Cancer Research (project No. 10068) and the Italian League against Cancer.

    View full text